Senior Vice President, Global Development and Medical Affairs · Xeris Biopharma Holdings, Inc. (XERS)

Ken Johnson

FY2024 is the first fiscal year CompBrief holds for Ken Johnson as a named executive officer of Xeris Biopharma; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,058,429

Salary $414,102Stock awards $430,500

6th of 6 named executive officers at Xeris Biopharma by FY2024 total.

6 named officers on file for Xeris Biopharma, FY2024

Ken Johnson’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • XERS’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Xeris Biopharma’s whole pay program stands against its peers

  • Xeris Biopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on XERS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 23, 2025 (DEF 14A).

Free

Get Ken Johnson’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Ken Johnson compensation by year

Xeris Biopharma Summary Compensation Table · the one fiscal year held
In US dollars, as Xeris Biopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$414,102
Bonus$0
Stock awards$430,500
Option awards$0
Non-equity incentive$182,205
Pension and deferred compensation$0
All other$31,622
Total$1,058,429

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Xeris Biopharma Holdings, Inc. DEF 14A filed April 23, 2025, accession 0001867096-25-000068, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Xeris Biopharma Holdings, Inc. filed document, accession 0001867096-25-000068. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU175,000$593,250—
RSU66,666$225,998—
RSU25,000$84,750—

Per the Outstanding Equity Awards at Fiscal Year-End table in Xeris Biopharma Holdings, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Xeris Biopharma’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Paul EdickFormer Chief Executive Officer$6,826,608
John ShannonChief Executive Officer$3,827,109
Beth HechtChief Legal Officer and Corporate Secretary$2,612,825
Kevin McCullochPresident and Chief Operating Officer$2,577,572
Steven PieperChief Financial Officer$1,854,017
Ken Johnson · this pageSenior Vice President, Global Development and Medical Affairs$1,058,429

The full Xeris Biopharma compensation record

free company brief

This page is one person within Xeris Biopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Xeris Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Ken Johnson's compensation dossier · One-time report. No refunds.